Meta-analyses of global trials finds in favor of aromatase inhibitors

December 12, 2008

SAN ANTONIO - Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Patients using aromatase inhibitors had more than a 3 percent lower cancer recurrence 6-8 years after diagnosis, compared to women using tamoxifen alone.

One of these studies also found a significant survival benefit (1.6 percent) for users of aromatase inhibitors, but researchers say not enough time has passed since treatment to judge with confidence whether one drug is superior to another in saving lives. The joint analyses are being presented at the Cancer Therapy & Research Center-American Association for Cancer Research (CTRC-AACR) 31st annual San Antonio Breast Cancer Symposium. "Tamoxifen is a good drug, but it looks like aromatase inhibitors may be somewhat better," says James Ingle, M.D., a professor of oncology at Mayo Clinic, who is presenting the results on behalf of the Aromatase Inhibitors Overview Group (AIOG).

"The importance of these findings can be seen from the fact that 80,000 to 90,000 women in the United States alone are using endocrine therapy this year," he says. "While a three percent difference in cancer recurrence may not seem like much, it can mean that several thousand women could be spared from a breast cancer recurrence."

This international group includes leaders of all the major clinical trials that tested aromatase inhibitors against use of tamoxifen. AIOG is a subset of the Early Breast Cancer Trials Collaborative Group (EBCTCG), a global organization of researchers that studies all randomized evidence of therapies used to treat breast cancer to find insights not apparent from examining individual trials - a technique known as a meta-analysis. The AIOG collaboration is led by Professor Mitch Dowsett of the Royal Marsden Hospital, London, UK.

Tamoxifen and aromatase inhibitors are widely used to prevent recurrence of, or to treat, tumors that are estrogen-receptor positive (ER+), which comprise 70 to 80 percent of all breast cancers.

While individual studies of tamoxifen and aromatase inhibitor drugs (including anastrozole, exemestane and letrozole) have found benefit for aromatase inhibitors, it was critically important that data from all of these studies be pooled and examined, Professor Dowsett says. "This kind of analysis provides knowledge on such end points as survival and allows us to have confidence that the improvement in preventing the return of breast cancer applies to all subgroups of patients but that those at greatest risk of recurrence have most to gain. That is not possible even with a large individual trial," he says. "The global community has come together to do this."

The researchers divided the major studies into two different cohorts, or groupings. Cohort 1 consists of clinical trials in which patients were randomized to treatment with either tamoxifen or aromatase inhibitors for five years. Two trials were examined (ATAC and BIG 1-98) that included 9,856 patients. Cohort 2 included studies in which breast cancer patients received tamoxifen for two to three years and then were randomized to complete their five years of adjuvant endocrine therapy with tamoxifen or to receive an aromatase inhibitor for the remainder of their five years of therapy. These studies (ABCSG 8, ARNO 95, IES/BIG 2-97, ITA) enrolled 9,015 patients.

The AIOG researchers found that in cohort 1, five years after beginning treatment, women using aromatase inhibitors had a 2.9 percent lower recurrence rate than those women who received tamoxifen; that decrease in recurrence rate increased to 3.9 percent at eight years after diagnosis. There were no statistically significant gains in survival between the two groups, Dr. Ingle says. "We need to follow these patients longer, for 10 to 15 years, to be sure of the effect on survival," he says.

In cohort 2, six years after the randomization, there was a 3.5 percent reduced risk of breast cancer recurrence in women who switched to aromatase inhibitors, compared to women who continued using tamoxifen. There was also a 1.6 percent reduced risk that patients using aromatase inhibitors would die from their disease - a statistically significant difference, Dr. Ingle says.

Professor Dowsett added, "These data should give clinicians and their patients greater confidence in understanding the relative effectiveness of these treatments in early breast cancer, but it is important to note that each drug is associated with its own set of side effects, and these also need to be considered in treatment decisions."

The researchers will continue mining the data in the future and specific projects are in the planning stages by the AIOG investigators. Dr. Ingle says, "The meta-analysis process provides the potential for learning more about cancer treatments than can be learned from individual clinical trials. The more we know, the better doctors can treat their patients."

Mayo Clinic

---

---

	Aromatase Inhibitors (Milestones in Drug Therapy) by B.J.A. Furr (Editor), William R. Miller (Editor), Angela Brodie (Editor), Robert Paridaens (Editor), J. Michael Dixon (Editor), Aman Buzdar (Editor), Evan Simpson (Editor), Per Eystein Lonning (Editor), Alan E. Wakeling (Editor) Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and...
	Aromatase Inhibitors: Types, Mode of Action and Indications (Cancer Etiology, Diagnosis and Treatment Series) by Jean R. Lamonte (Editor), Masanori Shirmodaira (Editor), Tomohiro Nakayama (Editor), Helena Aguilar (Editor), Ander Urruticoechea (Editor), Mosammat Rashida Begum (Editor) Aromatase inhibitors (AI) are a class of drugs used in the treatment of breast cancer and ovarian cancer in postmenopausal women. Aromatase is an enzyme that synthesises oestrogen and aromatase inhibitors block the synthesis of oestrogen, which is needed in some cancers to grow. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumour tissue. In contrast to pre-menopausal women, in whom most of the oestrogen is produced in the ovaries, in post-menopausal women most of the body's oestrogen is produced in the adrenal gland from the conversion of androgens. Investigations are ongoing to look for other applications and researchers continue to study aromatase inhibitors as a way to stimulate ovulation or suppress oestrogen...
	Aromatase Inhibitors for the Treatment of Breast Cancer by Matthew J. Ellis (Other Contributor)
	Gale Encyclopedia of Cancer: Aromatase inhibitors by R.N. Rhonda Cloos (Author) The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs, treatments, side effects and diagnostic procedures. Entries typically include the following elements: Causes and Symptoms Definition Description Diagnosis Prevention Resources Risks Special Concerns And more An appendix provides complete contact information for cancer centers, national support groups, government agencies and research groups. Features include anatomical...
	Aromatase inhibitors impressive against breast ca: adjuvant therapy.(Women's Health)(breast cancer): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2004. The length of the article is 1032 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Aromatase inhibitors impressive against breast ca: adjuvant therapy.(Women's Health)(breast cancer) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: February 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 3 Page: 62(1) Distributed by Thomson...
	Aromatase inhibitor impressive against breast ca.(Adjuvant Therapy): An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on February 15, 2004. The length of the article is 979 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Aromatase inhibitor impressive against breast ca.(Adjuvant Therapy) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: February 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 4 Page: 36(2) Distributed by Thomson...
	Aromatase inhibitors for breast Ca: new concerns. (Musculoskeletal Problems).: An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on February 15, 2003. The length of the article is 795 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Aromatase inhibitors for breast Ca: new concerns. (Musculoskeletal Problems). Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: February 15, 2003 Publisher: International Medical News Group Volume: 36 Issue: 4 Page: 49(1) Distributed by Thomson...
	Concerns crop up about aromatase inhibitors. (Adjuvant Therapy for Breast Cancer).: An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 15, 2003. The length of the article is 890 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Concerns crop up about aromatase inhibitors. (Adjuvant Therapy for Breast Cancer). Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: February 15, 2003 Publisher: International Medical News Group Volume: 33 Issue: 4 Page: 26(1) Article Type: Product/Service Evaluation Distributed by Thomson...
	Aromatase Inhibitors Topple Tamoxifen In Controlling Advanced Breast Cancer.(Brief Article): An article from: Family Practice News by International Medical News Group (Publisher) This digital document is an article from Family Practice News, published by International Medical News Group on April 1, 2001. The length of the article is 561 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Aromatase Inhibitors Topple Tamoxifen In Controlling Advanced Breast Cancer.(Brief Article) Publication: Family Practice News (Magazine/Journal) Date: April 1, 2001 Publisher: International Medical News Group Volume: 31 Issue: 7 Page: 26 Article Type: Brief Article, Product/Service Evaluation Distributed by Thomson...
	Tamoxifen-aromatase inhibitor combo improves Ca outcomes.(News): An article from: OB GYN News by Bruce Jancin (Author) This digital document is an article from OB GYN News, published by International Medical News Group on February 1, 2005. The length of the article is 609 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Tamoxifen-aromatase inhibitor combo improves Ca outcomes.(News) Author: Bruce Jancin Publication: OB GYN News (Magazine/Journal) Date: February 1, 2005 Publisher: International Medical News Group Volume: 40 Issue: 3 Page: 6(1) Distributed by Thomson...